Lung Cancer

Scott J. Antonia, MD, discusses how the combination of the PD-L1 inhibitor durvalumab and the CTLA-4 inhibitor tremelimumab, showed antitumor activity in patients with locally advanced or metastatic non–small cell lung cancer, irrespective of PD-L1 status.

Chandra P. Belani, MD, deputy director, Penn State Hershey Cancer Institute, Miriam Beckner Distinguished Professor of Medicine, Penn State Hershey College of Medicine, discusses atezolizumab in non-small cell lung cancer (NSCLC).

The FDA has approved crizotinib as a treatment for patients with ROS1-positive metastatic non–small cell lung cancer.

Benjamin Levy, MD, discusses how nivolumab and pembrolizumab have impacted the treatment landscape of NSCLC, how to choose between the two for patients, and what biomarkers are in development for PD-1/PD-L1 agents.

The FDA has accepted a supplemental new drug application for pembrolizumab as a treatment for patients with advanced non–small cell lung cancer with PD-L1 expression on ≥1% of tumors cells.

Chandra P. Belani, MD, Miriam Beckner Distinguished Professor of Medicine, Penn State Milton S. Hershey Medical Center, deputy director, Penn State Hershey Cancer Institute, discusses how the FDA approval of nivolumab (Opdivo) has impacted the treatment paradigm of non–small cell lung cancer (NSCLC).

Second- or third-line treatment with tremelimumab monotherapy failed to improve overall survival compared with placebo for patients with unresectable malignant mesothelioma.

The phase III SUNRISE trial comparing bavituximab plus docetaxel with docetaxel and placebo for patients with non–small cell lung cancer has been halted following a futility analysis.

Mark Socinski, MD, discusses the three generations of drugs are now available to treat patients with EGFR-mutant non–small cell lung cancer, and mutation testing for patients diagnosed with advanced or metastatic disease has been incorporated into clinical practice guidelines.

Pier Luigi Filosso, MD, associate professor of Thoracic Surgery, University of Torino, Italy, discusses future approaches to treating patients with neuroendocrine tumors of lung origin.